







C-reactive protein levels in early pregnancy, fetal
growth patterns, and the risk for neonatal
complications: the Generation R Study
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c
sOBJECTIVE: We sought to examine the associations of maternal C-re-
active protein (CRP) levels with fetal growth and the risks of neonatal
complications.
STUDY DESIGN: CRP levels were measured in early pregnancy in 6016
women. Main outcome measures were fetal growth in each trimester
and neonatal complications.
RESULTS: As compared to the reference group (CRP levels5mg/L), el-
vated maternal CRP levels (25 mg/L) were associated with lower esti-
ated fetal weight in third trimester and lower weight at birth (differences:
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132.e1 American Journal of Obstetrics& Gynecology AUGUST 201129 g, 95% confidence interval [CI], 58 to 0 and 128 g, 95% CI,
195 to60, respectively). Elevatedmaternal CRP levelswere also asso-
iated with an increased risk of a small size for gestational age in the off-
pring (adjusted odds ratio, 2.94; 95%CI, 1.61–5.36).
CONCLUSION: Maternal CRP levels in early pregnancy are associ-
ated with fetal growth restriction and increased risks of neonatal
complications.
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vC-reactive protein (CRP) is an acute-phase reactant and a frequently
sed marker of low-grade systemic in-
ammation. Its levels increase in re-
ponse to both infectious and noninfec-
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evels during pregnancy, as a marker of
ow-grade inflammation, have also been
uggested to be associatedwith increased
isks of fetal growth restriction and neo-
atal complications, such as preterm
irth, low birthweight, and small size for
estational age (SGA).6-8 Low-grade in-
ammation is associated with endothe-
ial dysfunction, leading to vascular
ysfunction and suboptimal placental
evelopment.Maternal systemic inflam-
ation might also be a response to isch-
mia of the placenta, due to suboptimal
lacentation.9,10 Subsequently, subopti-
al placental development might pre-
ispose mothers to increased risks for
arious pregnancy complications.11,12
Although the association of elevated
CRP levels with preterm birth has been
shown in several studies, results from
studies relating CRP levels with fetal
growth measures or neonatal complica-
tions are not consistent.7,8,13,14 Differ-
ences in results might be due to differ-
ences in study designs and populations. It
isnotknownwhetherand inwhich trimes-
terCRP levels affect fetal growthmeasures.











































































www.AJOG.org Obstetrics Researchwomen, we examined the associations of
maternal CRP levels, as marker of low-
grade inflammation in early pregnancy,
with fetal growth characteristics in dif-
ferent trimesters of pregnancy and the
risks of neonatal complications.
MATERIALS AND METHODS
Design and population
This study was embedded in the Gener-
ation R Study, a population-based pro-
spective cohort study from early fetal life
onward in the city of Rotterdam, The
Netherlands.15 Enrollment was aimed in
early pregnancy but was allowed until
birth of the child. All mothers were en-
rolled from 2001 through 2005. Re-
sponse rate was 61%.15 The study was
approved by the Medical Ethical Com-
mittee of the Erasmus MC, Rotterdam.
Written informed consent was obtained
from all participants.
Of the total of 8880mothers who were
enrolled during pregnancy, 76% (n 
6748) were enrolled before a gestational
age of 18 weeks.15 Of these mothers,
lood plasma samples were collected in
5% (n  6398) and CRP was success-
ully measured in 90% (n  6091).
others with extremely high CRP levels
100 mg/L) (n 6), and mothers with
win pregnancies (n  69) were ex-
luded, leaving 6016 mothers with sin-
leton live births for analysis (Supple-
entary Figure S1).
High-sensitivity CRP levels
Maternal venous blood samples were
collected in early pregnancy (median,
13.2; 95% range, 9.6–17.6 weeks) and
transported to the regional laboratory
(Star-MDC,Rotterdam,TheNetherlands)
for processing and storage.16 Blood sam-
les were stored at 80°C. CRP concen-
rations were measured in EDTA plasma




ensitivity in low ranges needed for pre-
icting future risk of events in apparently
ealthy individuals.17 CRP levels were
analyzed using an immunoturbidimetric
assay on the Architect System (Abbot
DiagnosticsB.V.,Hoofddorp,TheNether-
lands). The within run precision for CRPwas 1.3% at 12.9 mg/L and 1.2% at 39.9
mg/L. The lowest level of detectionwas 0.2
mg/L.We created 6 categories of CRP lev-
els (5.0, 5.0-9.9, 10.0-14.9, 15.0-19.9,
20.0-24.9, and 25 mg/L). Levels 5.0
g/L and 25 mg/L were considered
s low (reference) and elevated levels,
espectively.
Fetal growth characteristics
Fetal ultrasound examinations were
performed in 1 of the 2 dedicated re-
search centers in each trimester of
pregnancy. Median gestational age for
first, second, and third trimester visits
were 12.4 weeks (95% range, 10.7–14.5),
20.5 weeks (95% range, 18.7–23.1), and
30.4 weeks (95% range, 28.6–32.8), re-
spectively. In the second and third tri-
mester of pregnancy, we measured fetal
head circumference, abdominal circum-
ference, and femur length to the nearest
millimeter using standardized ultra-
sound procedures.18 Estimated fetal
eight was calculated using the formula
y Hadlock et al.19 Longitudinal growth
urves and gestational age-adjusted SD
cores (SDS) were constructed for all fe-
al growth measurements.20
Information about offspring sex, ges-
tational age,weight, length, andhead cir-
cumference at birth was obtained from
medical records and registries. Since
head circumference and length at birth
were not routinely measured at birth,
missing birth measures were completed
with data from the first-month visit at
the routine child health center. Preterm
birth was defined as a gestational age of
37 weeks at delivery, low birthweight
was defined as birthweight2500 g, and
SGA at birth was defined as a sex-specific
gestational age-adjusted birthweight be-
low the fifth percentile in the study co-




level, ethnicity and parity was obtained
by a questionnaire at enrollment in the
study. Maternal smoking and alcohol
consumption habits were assessed by
questionnaires in each trimester. Mater-
nal anthropometrics, including height
and weight, were measured without a
AUGUST 2011 Americshoes and heavy clothing and body mass
index (BMI) was calculated (weight/
height2 [kg/m2]) at enrollment.21Mater-
al systolic and diastolic blood pressure
eremeasured at intake, using standard-
zed methods. For each participant, the
ean value of 2 blood pressure readings
ver a 60-second interval was docu-
ented.22 Folate levels were analyzed
from venous samples drawn in the first
trimester of pregnancy. Maternal age
was registered at enrollment.
Statistical analysis
We assessed the associations of maternal
characteristics with CRP levels as out-
come levels using multivariate linear re-
gression models. Since CRP levels were
not normally distributed, we applied a
logarithmic transformation for these
analyses. Results are presented as geo-
metric means (95% range) per determi-
nant category and an overall P for trend
based on these regression models. Asso-
ciations of CRP levels with fetal growth
characteristics were assessed using linear
regression models. These models were
adjusted for gestational age at the mea-
surement, fetal sex, and maternal age,
BMI, education, ethnicity, parity, smok-
ing, alcohol consumption. BMI is known
to be highly correlated with levels of
CRP,23 and with birthweight,21,24 and
herefore expected to be our main con-
ounder. Further variableswere included
n these models based on their associa-
ion with both the CRP levels and preg-
ancy outcomes, or a 10% change in the
ffect estimate. Next, we assessed the as-
ociations of CRP level with the risks of
eonatal complications (preterm birth,
ow birthweight, and SGA). These mod-
ls were adjusted for maternal age, BMI,
ducation, ethnicity, parity, smoking, al-
ohol consumption and folic acid level at
ntake. Tests for trends were performed
sing CRP as continuous variable in
ultivariate linear and logistic regres-
ion analyses. The percentages of miss-
ng values within the population for
nalysis were 1% for continuous data
nd 13% for the categorical data. We
pplied multiple imputation for covari-
tes.25 Since there were no major differ-
nces in the observed results between
nalyses with imputed missing data or
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Research Obstetrics www.AJOG.orgcomplete cases only, only results includ-
ing imputed missing data are presented.
Allmeasures of association are presented
with their 95% confidence intervals
(CIs). All statistical analyses were per-
formed using the SPSS, version 17.0 for
Windows (SPSS Inc, Chicago, IL).
RESULTS
Maternal age ranged from 15.3–46.3
years, with a mean of 29.8 years (Table
1).Median CRP level was 4.5mg/L (95%
range, 0.60–25.46). Mean offspring
birthweight was 3420 g (SD 564), and
median gestational age at birth was 40.1
weeks (95% range, 35.6–42.3).Maternal
education, BMI, parity, and gestational
age were associated with CRP levels.
Mothers with a higher parity had a
higher mean CRP level (means for CRP
levels from 3.84 mg/L for a parity of
0-6.15 mg/L with a parity of 2) and
lowermaternal educationwas associated
with higher CRP levels (means for CRP
levels from 5.40 mg/L for mothers with
primary school only to 3.62 mg/L for
mothers with higher education). A
strong effect was seen for maternal BMI,
with monotonous increasing means for
CRP from 2.78 mg/L for the group with
BMI 20 to 10.87 mg/L for the group
ith BMI35 (Supplementary Table S1
and Supplementary Figure S2).
As compared to maternal CRP levels
of 5.0 mg/L, maternal CRP levels of
25mg/Lwere inversely associatedwith
estimated fetal weight in third trimester
and with birthweight (difference29 g,
95% CI, 58 to 0 and 128 g, 95% CI,
195 to 60, respectively). No consis-
ent associations were observed between
aternal CRP levels in early pregnancy
nd fetal head circumference in second
r third trimester or at birth (Table 2).
e used femur length in second and
hird trimester and body length at birth
s fetal length measures. Maternal CRP
evels were not consistently associated
ith fetal length. The Figure shows that,
s compared to levels of5.0 mg/L, the
elative effect of CRP levels of 25.0
g/L on fetal head circumference,
ength, and weight, presented as differ-
nce in SDS, tended to be greater at birth.
132.e3 American Journal of Obstetrics& GynecoloTABLE 1
Characteristics of study participants
Maternal characteristics at enrollment (n  6016) n
Age, y 29.8  5.1
..............................................................................................................................................................................................................................................
Height, cm 167.6  7.4
..............................................................................................................................................................................................................................................
Weight, kg 68.8  13.1
..............................................................................................................................................................................................................................................












Highest completed educational level
.....................................................................................................................................................................................................................................
Primary school 549 (9.1)
.....................................................................................................................................................................................................................................
Secondary school 2534 (42.1)
.....................................................................................................................................................................................................................................
































Gestational age at enrollment 13.2 (9.6–17.6)
..............................................................................................................................................................................................................................................
C-reactive protein level, mg/L 4.5 (0.60–25.46)
..............................................................................................................................................................................................................................................




Birthweight, g 3420  564
.....................................................................................................................................................................................................................................




Preterm birth, 37 wk 302 (5.0)
.....................................................................................................................................................................................................................................
Low birthweight, 2500 g 293 (4.9)
.....................................................................................................................................................................................................................................
Small size for gestational age, 5th percentile 299 (5.0)
..............................................................................................................................................................................................................................................
Values are presented as means (SD) or number (%).
Gestational age at enrollment and at birth andC-reactive protein level and folic acid level values are presented asmedian (95% range).gy AUGUST 2011
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C-reactive protein levels and fetal growth
Second trimester Third trimester Birth
Head circumference
















5.0 n  3162 Reference n  3153 Reference n  2638 Reference
................................................................................................................................................................................................................................................................................................................................................................................
5.0-9.9 n  1573 0.07 (0.44 to 0.31) n  1566 0.10 (0.45 to 0.66) n  1300 0.08 (1.05 to 0.88)
................................................................................................................................................................................................................................................................................................................................................................................
10.0-14.9 n  570 0.21 (0.77 to 0.35) n  563 0.34 (1.17 to 0.48) n  437 1.85 (3.33 to 0.36)
................................................................................................................................................................................................................................................................................................................................................................................
15.0-19.9 n  210 0.37 (1.24 to 0.50) n  206 0.07 (1.22 to 1.36) n  162 0.50 (2.80 to 1.81)
................................................................................................................................................................................................................................................................................................................................................................................
20.0-24.9 n  109 0.44 (0.73 to 1.61) n  107 1.21 (2.95 to 0.54) n  82 1.02 (4.18 to 2.14)
................................................................................................................................................................................................................................................................................................................................................................................
25.0 n  150 0.75 (1.76 to 0.25) n  153 0.51 (1.99 to 0.96) n  124 1.49 (4.08 to 1.10)
................................................................................................................................................................................................................................................................................................................................................................................
P for trend .240 .300 .109
Length
















5.0 n  3174 Reference n  3176 Reference n  2659 Reference
................................................................................................................................................................................................................................................................................................................................................................................
5.0-9.9 n 1569 0.10 (0.01 to 0.21) n  1578 0.03 (0.10 to 0.17) n  1313 0.01 (1.38 to 1.37)
................................................................................................................................................................................................................................................................................................................................................................................
10.0-14.9 n 575 0.08 (0.08 to 0.24) n  565 0.04 (0.16 to 0.24) n  458 1.00 (3.08 to 1.08)
................................................................................................................................................................................................................................................................................................................................................................................
15.0-19.9 n 210 0.03 (0.22 to 0.28) n  208 0.06 (0.25 to 0.37) n  168 0.23 (3.46 to 3.01)
................................................................................................................................................................................................................................................................................................................................................................................
20.0-24.9 n 109 0.22 (0.12 to 0.56) n  108 0.18 (0.25 to 0.37) n  80 3.08 (7.63 to 1.46)
................................................................................................................................................................................................................................................................................................................................................................................
25.0 n  150 0.18 (0.47 to 0.11) n 154 0.27 (0.63 to 0.09) n 126 2.74 (6.40 to 0.92)
................................................................................................................................................................................................................................................................................................................................................................................























5.0 n  3161 Reference n  3167 Reference n  3271 Reference
................................................................................................................................................................................................................................................................................................................................................................................
5.0-9.9 n  1559 1 (3 to 2) n  1570 7 (4 to 18) n 1630 10 (15 to 36)
................................................................................................................................................................................................................................................................................................................................................................................
10.0-14.9 n  575 1 (3 to 4) n  562 3 (20 to 13) n  586 47 (85 to 9)
................................................................................................................................................................................................................................................................................................................................................................................
15.0-19.9 n  209 0 (6 to 6) n  207 14 (12 to 46) n  221 28 (87 to 30)
................................................................................................................................................................................................................................................................................................................................................................................
20.0-24.9 n  109 3 (5 to 10) n  108 12 (23 to 46) n  112 86 (165 to 6)
................................................................................................................................................................................................................................................................................................................................................................................
25.0 n  150 6 (12 to 1) n  154 29 (58 to 0) n  159 128 (195 to 60)
................................................................................................................................................................................................................................................................................................................................................................................
P for trend .274 .115  .001
................................................................................................................................................................................................................................................................................................................................................................................
All models were adjusted for maternal age, body mass index, height, systolic and diastolic blood pressure at intake, education, ethnicity, parity, smoking, alcohol, folic acid level at intake, gestational
age at measurement, gestational age at blood collection, and fetal sex.
CI, confidence interval.










Research Obstetrics www.AJOG.orgTable 3 presents both the unadjusted
and adjusted associations of CRP levels
with the risks of neonatal complications.
The differences between the unadjusted
and adjusted models were mainly ex-
plained by including maternal BMI in
the models. The adjusted models show
that as compared to the reference cate-
gory (CRP levels 5.0 mg/L) mothers
with elevated CRP levels (25.0 mg/L)
were more likely to deliver children with
a SGA at birth (adjusted odds ratio, 2.94;
95% CI, 1.61–5.36). Mothers with ele-
vatedCRP levels (25.0mg/L) tended to
be more likely to deliver preterm (ad-
justed odds ratio, 1.42; 95% CI, 0.69–
2.89) or a child with a low birthweight
(adjusted odds ratio, 1.43; 95%CI, 0.67–
3.03), as compared to the reference cate-
gory, although not significantly.
COMMENT
In this population-based prospective co-
hort study, we observed associations of
maternal sociodemographic and anthro-
pometric measures and lifestyle habits
with CRP levels in early pregnancy. After
adjustment for these variables, elevated
maternal CRP levels (25.0 mg/L) in
early pregnancy were associated with fe-
tal growth restriction, and increased
risks of preterm birth and SGA at birth.
CRP is known to be slightly elevated
during pregnancy, due to the maternal
inflammatory reaction to the preg-
nancy.26 Previous studies showed that
easures of unhealthy lifestyle habits
uch as cigarette smoking are also asso-
iated with elevated CRP levels, whereas
oderate alcohol consumption and in-
reased physical activity are associated
ith lower CRP levels.27-29 Increased
BMI and adiposity are strongly associ-
ated with elevated CRP levels.30,31 In our
population-based cohort among preg-
nant women, maternal BMI, parity, and
smoking during pregnancy were all
positively associated with CRP levels.
Higher maternal education, European
background, and continuedmaternal al-
cohol consumptionwere associated with
lower CRP levels. Our results suggest
that markers of unhealthy lifestyle habits
lead to elevated CRP levels.
132.e5 American Journal of Obstetrics& GynecoloOur results indicate that elevated CRP
levels, as amarker ofmaternal low-grade
inflammation, are associated with fetal
growth restriction. The effect estimates
FIGURE
Elevated maternal C-reactive prote
and fetal growth characteristics
Values are regression coefficients (95% confide
SDS between elevated levels of maternal C-react
ompared to the reference group (5.0mg/L). A
ndex, height, systolic and diastolic blood pressu
lcohol, folic acid level at intake, gestational age
SDS, standard deviation score.
Ernst. C-reactive protein levels in pregnancy and fetal growthare relatively small. Our findings may be
gy AUGUST 2011important from an etiological perspec-
tive or on population level. Future stud-
ies should explore the role of CRP levels
in clinical practice.
levels
interval) and represent the difference in growth
protein levels in early pregnancy (25 mg/L) as
dels were adjusted for maternal age, bodymass
at intake, education, ethnicity, parity, smoking,
blood collection and fetal sex.

























www.AJOG.org Obstetrics Researchtween elevated maternal CRP levels in
early pregnancy and the risk of SGA,
which remained significant after adjust-
ment. The differences between the unad-
justed and adjusted models were mainly
explained by including maternal BMI in
the model. Maternal BMI is positively
associated with CRP levels32 and fetal
rowth.21 After adjusting our models for
aternal BMI, elevated CRP levels were
till associated with fetal growth restric-
TABLE 3





















































Adjusted odds ratios were adjusted for maternal age, body ma
and gestational age at blood collection.
CI, confidence interval.
Ernst. C-reactive protein levels in pregnancy and fetal groion and increased risks of SGA, suggest-ng that these associations are indepen-
ent of maternal BMI. Our results are in
ine with previous smaller studies, which
uggested an increased risk of preterm de-
ivery among mothers with elevated CRP
nearly ormid-pregnancy.However, these
tudies did not demonstrate associations
ith fetal growth retardation.7,14
The mechanisms underlying these as-
sociations should further be explored,
but might include that maternal low-
l complications




(95% CI) P value
1 1.00
.........................................................................................................................
8 1.26 (0.96–1.65) .10
.........................................................................................................................
0 1.62 (1.27–2.32) .01
.........................................................................................................................
7 1.85 (1.09–3.11) .02
.........................................................................................................................
7 1.49 (0.68–3.24) .32
.........................................................................................................................
9 1.34 (0.67–2.66) .42
.........................................................................................................................
.075




(95% CI) P value
4 1.00
.........................................................................................................................
4 1.09 (0.83–1.43) .54
.........................................................................................................................
1 1.12 (0.75–1.66) .59
.........................................................................................................................
1 1.05 (0.56–1.95) .89
.........................................................................................................................
5 0.94 (0.38–2.32) .89
.........................................................................................................................
8 1.05 (0.51–2.17) .90
.........................................................................................................................
.990




(95% CI) P value
8 1.00
.........................................................................................................................
3 0.86 (0.65–1.14) .30
.........................................................................................................................
9 0.96 (0.64–1.43) .82
.........................................................................................................................
0 0.87 (0.45–1.66) .67
.........................................................................................................................
5 0.86 (0.74–2.12) .74
.........................................................................................................................




ex, height, systolic and diastolic blood pressure at intake, educat
Am JObstet Gynecol 2011.grade systemic inflammation, indicated
AUGUST 2011 Americby elevated CRP levels, results in subop-
timal placental development,9,10 and
ubsequently increase the risks of preg-
ancy complications. However, higher
evels of CRPmay also be associatedwith
ascular dysfunction that leads in turn to
uboptimal placental development.9,10
Both fetal growth and pregnancy-in-
duced hypertensive disorders might
have at least part of their origin in sub-
optimal early placenta development.33
Adjusted odds ratio





















































































ss ind ion, eAlso, the associations might not reflect
an Journal of Obstetrics& Gynecology 132.e6
Research Obstetrics www.AJOG.orgcausality, since elevated CRP levels can
be markers of other risk factors or pro-
cesses leading fetal growth restriction.
Previous studies focused on the associa-
tions of CRP genotypes and levels with
cardiovascular disease, which used a
mendelian randomization approach,
suggested thatCRP is not causally related
to cardiovascular disease but rather a
marker of other risk factors.4,5,34 Such
studies have not yet been performed in
pregnancy.
Some methodological issues need to
be considered. To our knowledge, this is
the largest cohort study that has exam-
ined the associations of maternal CRP
levels in early pregnancy and placenta re-
lated complications inmother and child.
Of all mothers enrolled in pregnancy,
76% enrolled in early pregnancy.Nonre-
sponse at baseline would lead to selec-
tion bias if the associations would differ
between those with and without com-
plete data. This seems unlikely. Biased
estimates in large cohort studies primar-
ily arise from loss to follow-up rather
than from nonresponse at baseline.35
Since follow-up information at birth was
available in 93%,we donot expect biased
results due to loss to follow-up.We were
able to adjustmodels formultiple poten-
tial confounders, related to maternal so-
ciodemographic status, anthropomet-
rics, and lifestyle habits. However, as in
all observational studies, residual con-
founding due to unmeasured covariates
might still be the case.
In conclusion, maternal low-grade in-
flammation in early pregnancy, as mea-
sured by CRP levels, was associated with
fetal growth restriction and increased
risks of neonatal complications. Further
studies are needed to explore the under-
lyingmechanisms and causality for these
associations. f
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Flowchart of study participants
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Ernst. C-reactive protein levels in pregnancy and fetal groistics with C-reactive
n  6016 C-reactive protein, mg/L
...........................................................................................................................
n  204 3.42 (0.51–21.00)
...........................................................................................................................
n  965 4.61 (0.70–27.62)
...........................................................................................................................
n  1673 4.68 (0.60–27.01)
...........................................................................................................................
n  2337 4.12 (0.60–25.21)
...........................................................................................................................
n  759 4.18 (0.60–23.50)
...........................................................................................................................







n  542 2.78 (0.35–17.92)
...........................................................................................................................
n  3260 3.54 (0.60–20.75)
...........................................................................................................................
n  1453 5.58 (1.00–25.22)
...........................................................................................................................
n  470 8.45 (1.98–29.92)
...........................................................................................................................
n  229 10.87 (1.50–43.02)
...........................................................................................................................







n 3412 3.84 (0.60–23.07)
...........................................................................................................................
n 1797 4.67 (0.60–28.21)
...........................................................................................................................
n 756 6.15 (0.99–27.10)
...........................................................................................................................







n  549 5.40 (0.50–30.22)
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n  2534 4.75 (0.70–26.46)
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n  2505 3.62 (0.60–22.34)
...........................................................................................................................
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Values are presented as geometric means (95% range).
Values are based on multivariate linear regression models wit
Ernst. C-reactive protein levels in pregnancy and fetal groistics with C-reactive
ontinued)
n  6016 C-reactive protein, mg/L
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n  3502 3.95 (0.60–24.50)
...........................................................................................................................
n  2171 4.85 (0.60–27.07)
...........................................................................................................................







n  3865 4.23 (0.60–26.04)
...........................................................................................................................
n  480 3.95 (0.60–22.09)
...........................................................................................................................
n  908 4.60 (0.60–22.13)
...........................................................................................................................







n  2424 4.79 (0.60–26.18)
...........................................................................................................................
n  792 4.04 (0.70–22.25)
...........................................................................................................................
n  2065 3.80 (0.74–24.10)
...........................................................................................................................
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Correlation of gestational age and maternal BMI with CRP levels
Plots represent correlation of gestational age at blood collection and BMI at intake with CRP levels,
respectively. CRP was not normally distributed and therefore log transformation was performed.
BMI, body mass index; CRP, C-reactive protein.
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